BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Emirova K, Volokhina E, Tolstova E, van den Heuvel B. Recovery of renal function after long-term dialysis and resolution of cardiomyopathy in a patient with aHUS receiving eculizumab. BMJ Case Rep 2016;2016:bcr2015213928. [PMID: 26880823 DOI: 10.1136/bcr-2015-213928] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Borkar D, Schutt C, Verghese P. Renal Recovery Years After Initial Diagnosis of Hemolytic Uremic Syndrome. Clin Pediatr (Phila) 2018;57:861-4. [PMID: 28931327 DOI: 10.1177/0009922817732621] [Reference Citation Analysis]
2 Davis LS, Reimold AM. Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus. Rheumatology (Oxford). 2017;56:i100-i113. [PMID: 28375452 DOI: 10.1093/rheumatology/kew417] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
3 Fakhouri F, Zuber J, Frémeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet 2017;390:681-96. [PMID: 28242109 DOI: 10.1016/S0140-6736(17)30062-4] [Cited by in Crossref: 202] [Cited by in F6Publishing: 108] [Article Influence: 40.4] [Reference Citation Analysis]
4 Campbell CM, Cassol C, Cataland SR, Kahwash R. Atypical haemolytic uraemic syndrome: a case report of a rare cause of reversible cardiomyopathy. Eur Heart J Case Rep 2020;4:1-6. [PMID: 32352052 DOI: 10.1093/ehjcr/ytaa050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Alonso Valente R, García Rodríguez GE, García Marcote Y, Fidalgo Díaz M, Becerra Mosquera V, Novoa García D, Cordal Martínez T, Díaz Rodríguez C. Discontinuation of Peritoneal Dialysis after Late Initiation of Eculizumab in a Case of Familial Atypical Hemolytic-Uremic Syndrome: A Case Report. Case Rep Nephrol Dial 2017;7:18-25. [PMID: 28612003 DOI: 10.1159/000457950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Haskin O, Falush Y, Davidovits M. Is eculizumab indicated in patients with atypical hemolytic uremic syndrome already on prolonged dialysis? A case report and review of the literature. Pediatr Nephrol 2019;34:2601-4. [DOI: 10.1007/s00467-019-04341-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Lavrishcheva YV, Yakovenko AA, Kudlai DA. [The experience of using the Russian biosimilar of the original drug eculizumab for the treatment of patients with atypical hemolytic-uremic syndrome]. Ter Arkh 2020;92:76-80. [PMID: 33346497 DOI: 10.26442/00403660.2020.06.000649] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Kozlovskaya NL, Korotchaeva YV, Bobrova LA. Adverse outcomes in obstetric-atypical haemolytic uraemic syndrome: a case series analysis. J Matern Fetal Neonatal Med 2019;32:2853-9. [PMID: 29606012 DOI: 10.1080/14767058.2018.1450381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]